

Antonella d'Arminio Monforte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7215951/publications.pdf>

Version: 2024-02-01

360
papers

31,501
citations

8755

75
h-index

4645

170
g-index

368
all docs

368
docs citations

368
times ranked

24486
citing authors

#	ARTICLE	IF	CITATIONS
1	Compassionate Use of Remdesivir for Patients with Severe Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 2327-2336.	27.0	2,241
2	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2003, 349, 1993-2003.	27.0	1,560
3	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet, The</i> , 2002, 360, 119-129.	13.7	1,415
4	Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2007, 356, 1723-1735.	27.0	1,393
5	Changing patterns of mortality across Europe in patients infected with HIV-1. <i>Lancet, The</i> , 1998, 352, 1725-1730.	13.7	1,182
6	Decline in the AIDS and death rates in the EuroSIDA study: an observational study. <i>Lancet, The</i> , 2003, 362, 22-29.	13.7	1,157
7	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. <i>Archives of Internal Medicine</i> , 2006, 166, 1632.	3.8	1,004
8	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. <i>Lancet, The</i> , 2008, 371, 1417-1426.	13.7	809
9	Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. <i>Lancet HIV,the</i> , 2017, 4, e349-e356.	4.7	805
10	Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , 2003, 17, 1179-1193.	2.2	770
11	Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. <i>Lancet, The</i> , 2014, 384, 241-248.	13.7	767
12	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. <i>Lancet, The</i> , 2009, 373, 1352-1363.	13.7	676
13	Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , 2010, 201, 318-330.	4.0	575
14	Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. <i>Aids</i> , 2000, 14, 499-507.	2.2	483
15	Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients. <i>Diabetes Care</i> , 2008, 31, 1224-1229.	8.6	448
16	Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 445-449.	2.1	405
17	Correlates and Predictors of Adherence to Highly Active Antiretroviral Therapy: Overview of Published Literature. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S123-S127.	2.1	390
18	Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. <i>Aids</i> , 2010, 24, 1537-1548.	2.2	381

#	ARTICLE	IF	CITATIONS
19	Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , 2003, 17, 1179-93.	2.2	335
20	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 491-501.	2.8	309
21	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.	13.7	303
22	Late Diagnosis of HIV Infection: Epidemiological Features, Consequences and Strategies to Encourage Earlier Testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, S3-S8.	2.1	274
23	Changing incidence of central nervous system diseases in the EuroSIDA cohort. <i>Annals of Neurology</i> , 2004, 55, 320-328.	5.3	273
24	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2019, 393, 143-155.	13.7	265
25	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. <i>Aids</i> , 2007, 21, 1185-1197.	2.2	264
26	Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. <i>Aids</i> , 2002, 16, 1663-1671.	2.2	259
27	Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. <i>Aids</i> , 2008, 22, 2035-2038.	2.2	256
28	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013, 10, e1001510.	8.4	256
29	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV,the</i> , 2015, 2, e98-e106.	4.7	249
30	Depressive Symptoms, Neurocognitive Impairment, and Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Persons. <i>Psychosomatics</i> , 2004, 45, 394-402.	2.5	231
31	Female gender is associated with long COVID syndrome: a prospective cohort study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 611.e9-611.e16.	6.0	230
32	All-cause mortality in treated HIV-infected adults with CD4 >=500/mm ³ compared with the general population: evidence from a large European observational cohort collaboration. <i>International Journal of Epidemiology</i> , 2012, 41, 433-445.	1.9	217
33	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. <i>Lancet, The</i> , 2006, 368, 451-458.	13.7	209
34	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , 2008, 22, 2143-2153.	2.2	207
35	Discontinuation of <i>Pneumocystis carinii</i> pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. <i>Lancet, The</i> , 1999, 353, 1293-1298.	13.7	206
36	Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. <i>Clinical Infectious Diseases</i> , 2005, 41, 1772-1782.	5.8	197

#	ARTICLE	IF	CITATIONS
37	Response to combination antiretroviral therapy: variation by age. <i>Aids</i> , 2008, 22, 1463-1473.	2.2	188
38	An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 214-223.	1.8	180
39	Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. <i>International Journal of Epidemiology</i> , 2009, 38, 1624-1633.	1.9	173
40	Mother-to-Child Transmission of Hepatitis C Virus Detected by Nested Polymerase Chain Reaction. <i>Journal of Infectious Diseases</i> , 1992, 165, 720-723.	4.0	161
41	Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). <i>Journal of NeuroVirology</i> , 2003, 9, 47-53.	2.1	157
42	Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. <i>Lancet HIV</i> , 2016, 3, e23-e32.	4.7	157
43	Discontinuation of Secondary Prophylaxis against <i>Pneumocystis carinii</i> Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2001, 344, 168-174.	27.0	155
44	Microbial translocation predicts disease progression of HIV-infected antiretroviral-naïve patients with high CD4+ cell count. <i>Aids</i> , 2011, 25, 1385-1394.	2.2	155
45	The Absence of CD4+T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options. <i>Clinical Infectious Diseases</i> , 2009, 48, 328-337.	5.8	150
46	Delayed Presentation and Late Testing for HIV: Demographic and Behavioral Risk Factors in a Multicenter Study in Italy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 951-959.	2.1	149
47	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2015, 211, 178-186.	4.0	146
48	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.5	145
49	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e8-e16.	2.1	142
50	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	5.8	140
51	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 59, 287-297.	5.8	136
52	Prevalence, Associated Factors, and Prognostic Determinants of AIDS-Related Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 1681-1691.	5.8	131
53	The Coding Causes of Death in HIV (CoDe) Project. <i>Epidemiology</i> , 2011, 22, 516-523.	2.7	129
54	Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. <i>Aids</i> , 2006, 20, 1727-1736.	2.2	127

#	ARTICLE	IF	CITATIONS
55	The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy. <i>Archives of Internal Medicine</i> , 2005, 165, 416.	3.8	124
56	Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. <i>Cancer</i> , 2010, 116, 5306-5315.	4.1	120
57	Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study. <i>Clinical Infectious Diseases</i> , 2004, 38, 565-571.	5.8	118
58	A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2002, 185, 178-187.	4.0	116
59	Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy. <i>Journal of Medical Virology</i> , 2021, 93, 1175-1179.	5.0	115
60	Global initiative for meticillin-resistant <i>Staphylococcus aureus</i> pneumonia (GLIMP): an international, observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1364-1376.	9.1	109
61	Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal. <i>Clinical Infectious Diseases</i> , 2009, 48, 1138-1151.	5.8	108
62	Long-Lasting Cognitive Abnormalities after COVID-19. <i>Brain Sciences</i> , 2021, 11, 235.	2.3	107
63	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2005, 10, 811-823.	1.0	103
64	Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. <i>Aids</i> , 2004, 18, 227-235.	2.2	102
65	Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 930-940.	3.0	102
66	Evidence for Polymicrobial Flora Translocating in Peripheral Blood of HIV-Infected Patients with Poor Immune Response to Antiretroviral Therapy. <i>PLoS ONE</i> , 2011, 6, e18580.	2.5	97
67	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥ 200 Cells/ μ L in the Post-Combination Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2013, 57, 1038-1047.	5.8	92
68	Potential predictive factors of osteoporosis in HIV-positive subjects. <i>Bone</i> , 2006, 38, 893-897.	2.9	90
69	Body Habitus Changes and Metabolic Alterations in Protease Inhibitor-Naive HIV-1-Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 21-31.	2.1	89
70	Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. <i>Aids</i> , 2013, 27, 407-415.	2.2	89
71	Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus. <i>Circulation</i> , 2009, 119, 805-811.	1.6	88
72	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. <i>Clinical Infectious Diseases</i> , 2013, 56, 888-897.	5.8	88

#	ARTICLE	IF	CITATIONS
73	When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. <i>Aids</i> , 2001, 15, 983-990.	2.2	87
74	Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0160460.	2.5	86
75	Hepatitis delta in HIV-infected individuals in Europe. <i>Aids</i> , 2011, 25, 1987-1992.	2.2	79
76	High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. <i>Aids</i> , 2010, 24, 427-435.	2.2	76
77	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clinical Infectious Diseases</i> , 2017, 65, 959-966.	5.8	75
78	Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. <i>Aids</i> , 2013, 27, 769-779.	2.2	70
79	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015, 20, .	7.0	70
80	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 471.	2.9	68
81	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. <i>Nature Communications</i> , 2021, 12, 4450.	12.8	67
82	Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. <i>Antiviral Therapy</i> , 2008, 13, 959-967.	1.0	65
83	Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study. <i>Journal of NeuroVirology</i> , 2001, 7, 364-368.	2.1	64
84	Access to Antiretroviral Treatment, Incidence of Sustained Therapy Interruptions, and Risk of Clinical Events According to Sex. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 184-190.	2.1	64
85	Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors. <i>Journal of Virology</i> , 2006, 80, 7186-7198.	3.4	64
86	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>International Journal of Epidemiology</i> , 2014, 43, 691-702.	1.9	64
87	Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors. <i>Journal of Virology</i> , 2007, 81, 11507-11519.	3.4	62
88	Medical and Societal Consequences of Late Presentation. <i>Antiviral Therapy</i> , 2010, 15, 9-15.	1.0	61
89	T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis. <i>PLoS ONE</i> , 2012, 7, e46073.	2.5	61
90	Patient-reported and physician-estimated adherence to HAART. <i>Journal of General Internal Medicine</i> , 2004, 19, 1104-1110.	2.6	60

#	ARTICLE	IF	CITATIONS
91	Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. <i>PLoS ONE</i> , 2017, 12, e0186638.	2.5	59
92	Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2015-2025.	3.2	58
93	Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. <i>Aids</i> , 2003, 17, 1099-1102.	2.2	58
94	AIDS-defining diseases in 250 HIV-infected patients; a comparative study of clinical and autopsy diagnoses. <i>Aids</i> , 1992, 6, 1159-1164.	2.2	57
95	Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2305-2318.	3.0	57
96	Reorienting health systems to care for people with HIV beyond viral suppression. <i>Lancet HIV</i> , 2019, 6, e869-e877.	4.7	57
97	Occult hepatitis B virus infection in a Cohort of HIV-positive patients: Correlation with hepatitis C virus coinfection, virological and immunological features. <i>Infection</i> , 2009, 37, 445-449.	4.7	56
98	Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990-2014. <i>Journal of Hepatology</i> , 2017, 67, 255-262.	3.7	56
99	Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid-Lowering Drugs in HIV-Infected Individuals and Impact on Myocardial Infarction. <i>Clinical Infectious Diseases</i> , 2008, 46, 1101-1110.	5.8	55
100	Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy. <i>Aids</i> , 2016, 30, 991-1003.	2.2	55
101	Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. <i>Journal of the International AIDS Society</i> , 2012, 15, 17426.	3.0	54
102	One-year cognitive follow-up of COVID-19 hospitalized patients. <i>European Journal of Neurology</i> , 2022, 29, 2006-2014.	3.3	54
103	Risk of Developing Specific AIDS-Defining Illnesses in Patients Coinfected with HIV and Hepatitis C Virus With or Without Liver Cirrhosis. <i>Clinical Infectious Diseases</i> , 2009, 49, 612-622.	5.8	53
104	Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. <i>Aids</i> , 2004, 18, 11-19.	2.2	52
105	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. <i>Aids</i> , 2008, 22, 2461-2469.	2.2	51
106	Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 548-555.	3.0	51
107	The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. <i>BMC Infectious Diseases</i> , 2013, 13, 414.	2.9	51
108	Associations between immune depression and cardiovascular events in HIV infection. <i>Aids</i> , 2013, 27, 2735-2748.	2.2	51

#	ARTICLE	IF	CITATIONS
109	High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations. <i>Journal of Virology</i> , 2005, 79, 10718-10729.	3.4	50
110	Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. <i>Aids</i> , 2016, 30, 1731-1743.	2.2	50
111	Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. <i>Antiviral Therapy</i> , 2008, 13, 959-67.	1.0	50
112	Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. <i>Aids</i> , 2008, 22, 1769-1778.	2.2	48
113	Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. <i>Journal of Translational Medicine</i> , 2013, 11, 51.	4.4	48
114	Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. <i>Lancet HIV</i> , 2022, 9, e474-e485.	4.7	48
115	Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 407-416.	2.1	46
116	Role of Hepatitis C Virus (HCV) Viremia and HCV Genotype in the Immune Recovery from Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naïve HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2005, 40, e101-e109.	5.8	46
117	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. <i>Clinical Infectious Diseases</i> , 2017, 64, 1644-1656.	5.8	46
118	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNa cohort. <i>Journal of the International AIDS Society</i> , 2019, 22, e25227.	3.0	46
119	Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness. <i>Frontiers in Immunology</i> , 2020, 11, 580987.	4.8	46
120	Late Presenters in New HIV Diagnoses from An Italian Cohort of HIV-Infected Patients: Prevalence and Clinical Outcome. <i>Antiviral Therapy</i> , 2011, 16, 1103-1112.	1.0	45
121	Is Moderate HIV Viremia Associated With a Higher Risk of Clinical Progression in HIV-Infected People Treated With Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 23-30.	2.1	44
122	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	1.9	43
123	Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?. <i>Journal of Hepatology</i> , 2013, 59, 213-220.	3.7	41
124	Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 348-354.	2.1	41
125	Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 229-237.	2.1	40
126	Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. <i>Aids</i> , 2009, 23, 2199-2208.	2.2	40

#	ARTICLE	IF	CITATIONS
127	Discontinuation of Secondary Prophylaxis for <i>Pneumocystis carinii</i> Pneumonia in Human Immunodeficiency Virus-Infected Patients: A Randomized Trial by the CIOP Study Group. <i>Clinical Infectious Diseases</i> , 2003, 36, 645-651.	5.8	39
128	Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. <i>Aids</i> , 2011, 25, 1497-1504.	2.2	39
129	Delayed HIV diagnosis and initiation of antiretroviral therapy. <i>Aids</i> , 2014, 28, 2297-2306.	2.2	39
130	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 263-271.	2.1	39
131	Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis. <i>Antiviral Therapy</i> , 2006, 11, 567-574.	1.0	38
132	Highly Active Antiretroviral Therapy Reduces the Age-Associated Risk of Dementia in a Cohort of Older HIV-1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 386-392.	1.1	37
133	Bacterial coinfections in dengue virus disease: what we know and what is still obscure about an emerging concern. <i>Infection</i> , 2017, 45, 1-10.	4.7	36
134	Predictors of cytomegalovirus disease, natural history and autopsy findings in a cohort of patients with AIDS. <i>Aids</i> , 1997, 11, 517-524.	2.2	35
135	HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 1077-1086.	1.0	35
136	Long-term exposure to combination antiretroviral therapy and risk of death from specific causes. <i>Aids</i> , 2012, 26, 315-323.	2.2	35
137	Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. <i>Aids</i> , 2001, 15, 1733-1736.	2.2	35
138	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>International Journal of Epidemiology</i> , 2012, 41, 1807-1820.	1.9	34
139	Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 1212-1220.	4.0	34
140	Self-Reported Sexual Dysfunction Is Frequent Among HIV-Infected Persons and Is Associated with Suboptimal Adherence to Antiretrovirals. <i>AIDS Patient Care and STDs</i> , 2008, 22, 291-299.	2.5	33
141	Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals: Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study. <i>Diabetes Care</i> , 2009, 32, 474-480.	8.6	33
142	Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. <i>Aids</i> , 2010, 24, 1455-1460.	2.2	33
143	Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?. <i>Liver International</i> , 2015, 35, 2384-2391.	3.9	33
144	Relative Prognostic Value of Self-Reported Adherence and Plasma Nrti/Pi Concentrations to Predict Virological Rebound in Patients Initially Responding to Haart. <i>Antiviral Therapy</i> , 2004, 9, 291-296.	1.0	32

#	ARTICLE	IF	CITATIONS
145	Clinical diagnosis of mycobacterial diseases versus autopsy findings in 350 patients with AIDS. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1996, 15, 453-458.	2.9	31
146	Multiple viral infections. <i>Journal of Hepatology</i> , 2006, 44, S108-S113.	3.7	31
147	Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study "2012-2015". <i>PLoS ONE</i> , 2019, 14, e0220108.	2.5	31
148	Prevalence and risk factors for <i>Enterobacteriaceae</i> in patients hospitalized with community-acquired pneumonia. <i>Respirology</i> , 2020, 25, 543-551.	2.3	31
149	Behavioral Correlates of Adherence to Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S145-S148.	2.1	30
150	Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. <i>International Journal of Antimicrobial Agents</i> , 2005, 26, 88-91.	2.5	30
151	Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral Therapy. <i>Frontiers in Immunology</i> , 2016, 7, 614.	4.8	30
152	Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. <i>PLoS ONE</i> , 2017, 12, e0186549.	2.5	29
153	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz330.	0.9	28
154	Outcome of a Second-Line Protease Inhibitor-Containing Regimen in Patients Failing or Intolerant of a First Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 115-122.	2.1	27
155	Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. <i>Clinical Microbiology and Infection</i> , 2016, 22, 191-200.	6.0	27
156	HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2051-2070.	4.0	26
157	Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals. <i>Antiviral Therapy</i> , 2005, 10, 109-117.	1.0	26
158	Impaired CD4 T-Cell Count Response to Combined Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients Presenting With Tuberculosis as AIDS-Defining Condition. <i>Clinical Infectious Diseases</i> , 2012, 54, 853-861.	5.8	25
159	Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1271-1279.	4.4	25
160	Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. <i>American Journal of Hematology</i> , 2012, 87, 749-753.	4.1	24
161	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. <i>BMC Medicine</i> , 2018, 16, 79.	5.5	24
162	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 292-300.	2.1	24

#	ARTICLE	IF	CITATIONS
163	The EuroSIDA study: 25 years of scientific achievements. <i>HIV Medicine</i> , 2020, 21, 71-83.	2.2	24
164	Viral Interference Between Hepatitis B, C, and D Viruses in Dual and Triple Infections in HIV-Positive Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 574-581.	2.1	23
165	Life Expectancy in the Immune Recovery Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 175-181.	2.1	23
166	Declining Incidence of AIDS and Increasing Prevalence of AIDS Presenters Among AIDS Patients in Italy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003, 22, 663-669.	2.9	22
167	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression. <i>Aids</i> , 2014, 28, 2269-2279.	2.2	22
168	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. <i>International Journal of Epidemiology</i> , 2017, 46, dyw211.	1.9	22
169	Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5925.	4.1	22
170	Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers. <i>EClinicalMedicine</i> , 2021, 36, 100914.	7.1	22
171	Psychological outcomes after hospitalization for COVID-19: data from a multidisciplinary follow-up screening program for recovered patients. <i>Research in Psychotherapy: Psychopathology, Process and Outcome</i> , 2020, 23, 491.	0.8	22
172	Outcome of a Second-Line Protease Inhibitor-Containing Regimen in Patients Failing or Intolerant of a First Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 24, 115-122.	2.1	21
173	Reduced CD127 expression on peripheral CD4+ T cells impairs immunological recovery in course of suppressive highly active antiretroviral therapy. <i>Aids</i> , 2010, 24, 2590-2593.	2.2	21
174	Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 650-657.	5.8	21
175	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1363-1367.	3.0	21
176	Virological Success of Lopinavir/Ritonavir Salvage Regimen is Affected by an Increasing Number of Lopinavir/Ritonavir-Related Mutations. <i>Antiviral Therapy</i> , 2003, 8, 209-214.	1.0	21
177	Role of <i>In Vitro</i> Stimulation with Lipopolysaccharide on T-Cell Activation in HIV-Infected Antiretroviral-Treated Patients. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	20
178	Assessment of radiological vertebral fractures in HIV-infected patients: clinical implications and predictive factors. <i>HIV Medicine</i> , 2015, 16, 563-571.	2.2	20
179	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw009.	0.9	20
180	Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study. <i>Antiviral Therapy</i> , 2016, 21, 495-506.	1.0	20

#	ARTICLE	IF	CITATIONS
181	Association Between Impaired VÎ±7.2+CD161++CD8+ (MAIT) and VÎ±7.2+CD161-CD8+ T-Cell Populations and Gut Dysbiosis in Chronically HIV- and/or HCV-Infected Patients. <i>Frontiers in Microbiology</i> , 2019, 10, 1972.	3.5	20
182	Prevalence of HIV-1 Primary Drug Resistance in Seroconverters of the ICoNA Cohort Over the Period 1996-2001. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 761-764.	2.1	19
183	Comparative Effectiveness of Initial Antiretroviral Therapy Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 253-260.	2.1	19
184	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , 2018, 18, 870.	2.9	19
185	Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities. <i>Aids</i> , 2019, 33, 759-762.	2.2	19
186	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019, 20, 99-109.	2.2	19
187	The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, Italy. <i>Frontiers in Public Health</i> , 2020, 8, 575029.	2.7	19
188	Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison. <i>Antiviral Therapy</i> , 2006, 11, 609-618.	1.0	19
189	Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?. <i>Aids</i> , 2008, 22, 2481-2492.	2.2	18
190	CD8+ Hyperactivation and Senescence Correlate With Early Carotid Intima-Media Thickness in HIV+ Patients With No Cardiovascular Disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 642-644.	2.1	18
191	Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes. <i>Frontiers in Immunology</i> , 2021, 12, 639291.	4.8	18
192	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. <i>PLoS Medicine</i> , 2017, 14, e1002424.	8.4	17
193	Predicting the magnitude of short-term CD4 ⁺ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 165-175.	1.0	16
194	Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis. <i>PLoS ONE</i> , 2011, 6, e26009.	2.5	16
195	What Do We Know about Antiretroviral Treatment of HIV in Women?. <i>Antiviral Therapy</i> , 2013, 18, 27-34.	1.0	16
196	Brief Report: Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 347-352.	2.1	16
197	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa456.	0.9	16
198	Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 579-586.	2.1	16

#	ARTICLE	IF	CITATIONS
199	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment—Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	5.8	16
200	Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems. <i>Antiviral Therapy</i> , 2004, 9, 743-752.	1.0	16
201	Predictive Factors of Hyperlipidemia in HIV-Infected Subjects Receiving Lopinavir/Ritonavir. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 132-138.	1.1	15
202	Immunophenotype and Function of CD38-Expressing CD4+ and CD8+ T Cells in HIV-Infected Patients Undergoing Suppressive Combination Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 1511-1513.	4.0	15
203	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. <i>PLoS ONE</i> , 2017, 12, e0177402.	2.5	15
204	Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. <i>EClinicalMedicine</i> , 2019, 13, 91-100.	7.1	15
205	What do the changing patterns of comorbidity burden in people living with HIV mean for long-term management? Perspectives from European HIV cohorts. <i>HIV Medicine</i> , 2020, 21, 3-16.	2.2	15
206	Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era. <i>Aids</i> , 2021, 35, 1103-1112.	2.2	15
207	Incidence, Timing, and Determinants of Bacterial Pneumonia Among HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 339-345.	2.1	14
208	Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+. <i>Aids</i> , 2018, 32, 1361-1367.	2.2	14
209	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3295-3304.	3.0	14
210	Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies. <i>International Journal of Cancer</i> , 2020, 146, 3134-3146.	5.1	14
211	Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2021, 174, 768-776.	3.9	14
212	Economic evaluation of HIV treatments: The I.CO.N.A. cohort study. <i>Health Policy</i> , 2005, 74, 304-313.	3.0	13
213	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. <i>PLoS ONE</i> , 2017, 12, e0177352.	2.5	13
214	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018, 19, 475-484.	2.2	13
215	Successful direct-acting antiviral therapy in HIV/HCV co-infected patients fails to restore circulating mucosal-associated invariant T cells. <i>European Journal of Immunology</i> , 2019, 49, 1127-1129.	2.9	13
216	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. <i>New Microbiologica</i> , 2016, 39, 93-109.	0.1	13

#	ARTICLE	IF	CITATIONS
217	Simplification of Protease Inhibitor-Containing Regimens with Efavirenz, Nevirapine or Abacavir: Safety and Efficacy Outcomes. <i>Antiviral Therapy</i> , 2003, 8, 27-35.	1.0	13
218	Reduced Central Memory CD4+ T Cells and Increased T-Cell Activation Characterise Treatment-Naive Patients Newly Diagnosed at Late Stage of HIV Infection. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-10.	0.7	12
219	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. <i>Journal of the National Cancer Institute</i> , 2018, 110, 598-607.	6.3	12
220	Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a PegIFN α add-on strategy: A randomized study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 381-390.	2.0	12
221	Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015. <i>Clinical Microbiology and Infection</i> , 2018, 24, 422-427.	6.0	12
222	The importance of patients' case-mix for the correct interpretation of the hospital fatality rate in COVID-19 disease. <i>International Journal of Infectious Diseases</i> , 2020, 100, 67-74.	3.3	12
223	Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?. <i>HIV Medicine</i> , 2021, 22, 140-145.	2.2	12
224	The impact of DAA-mediated HCV eradication on CD4 ⁺ and CD8 ⁺ T lymphocyte trajectories in HIV/HCV coinfecting patients: Data from the ICONA Foundation Cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 779-786.	2.0	12
225	Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). <i>Journal of NeuroVirology</i> , 2003, 9, 47-53.	2.1	12
226	Insurability of HIV-positive people treated with antiretroviral therapy in Europe. <i>Aids</i> , 2013, 27, 1641-1655.	2.2	11
227	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4 ⁺ counts \leq 200 cells/mm ³ and HIV-RNA \geq 5 log ₁₀ copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2732-2741.	3.0	11
228	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. <i>Journal of Clinical Virology</i> , 2020, 130, 104534.	3.1	11
229	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. <i>Viruses</i> , 2020, 12, 791.	3.3	11
230	Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?. <i>International Journal of Infectious Diseases</i> , 2020, 99, 75-76.	3.3	11
231	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. <i>PLoS ONE</i> , 2017, 12, e0187393.	2.5	11
232	Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. <i>New Microbiologica</i> , 2018, 41, 247-255.	0.1	11
233	The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?. <i>Antiviral Therapy</i> , 2004, 9, 811-817.	1.0	11
234	Reduced HIV symptoms and improved health-related quality of life correlate with better access to care for HIV-1 infected women: the ELLA study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19616.	3.0	10

#	ARTICLE	IF	CITATIONS
235	Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy—Experienced Patients: A Multicenter Clinical Experience. <i>HIV Clinical Trials</i> , 2014, 15, 140-150.	2.0	10
236	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. <i>Aids</i> , 2016, 30, 1583-1596.	2.2	10
237	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2663-2669.	3.0	10
238	Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets. <i>BMC Infectious Diseases</i> , 2019, 19, 881.	2.9	10
239	Declining Mortality Rate of Hospitalised Patients in the Second Wave of the COVID-19 Epidemics in Italy: Risk Factors and the Age-Specific Patterns. <i>Life</i> , 2021, 11, 979.	2.4	10
240	Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	10
241	Estimating duration of HIV infection with CD4 cell count and HIV-1 RNA at presentation. <i>Aids</i> , 2001, 15, 2201-2203.	2.2	9
242	Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy. <i>Pathogens and Global Health</i> , 2023, 117, 181-189.	2.3	9
243	Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2205-2209.	3.0	8
244	Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. <i>Aids</i> , 2016, 30, 1629-1637.	2.2	8
245	European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements. <i>HIV Medicine</i> , 2016, 17, 445-452.	2.2	8
246	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw846.	5.8	8
247	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1637-1642.	3.0	8
248	Out of focus: tailoring the cascade of care to the needs of women living with HIV. <i>HIV Medicine</i> , 2017, 18, 3-17.	2.2	8
249	Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection. <i>HIV Medicine</i> , 2018, 19, 132-142.	2.2	8
250	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3460-3470.	3.0	8
251	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , 2019, 220, 1629-1634.	4.0	8
252	Virological response and retention in care according to time of starting ART in Italy: data from the IcoNa Foundation Study cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 681-689.	3.0	8

#	ARTICLE	IF	CITATIONS
253	Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles?. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa340.	0.9	8
254	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021, 73, 195-202.	5.8	8
255	The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series. <i>Aids</i> , 2021, 35, 2341-2346.	2.2	8
256	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , 2020, 15, e0243625.	2.5	8
257	Italian multicentre study of didanosine compassionate use in advanced HIV infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1997, 16, 135-142.	2.9	7
258	Long-term antiretroviral efficacy and safety of lopinavir/ritonavir in HAART-experienced subjects: 4 year follow-up study. <i>Aids</i> , 2005, 19, 1934-1936.	2.2	7
259	Untangling the Immunological Implications of Nadir on CD4+ Cell Recovery during Suppressive Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 46, 149-150.	5.8	7
260	HPV Infection in a Cohort of HIV-Positive Men and Women: Prevalence of Oncogenic Genotypes and Predictors of Mucosal Damage at Genital and Oral Sites. <i>Journal of Sexually Transmitted Diseases</i> , 2013, 2013, 1-8.	1.0	7
261	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , 2015, 10, e0124252.	2.5	7
262	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015, 10, e0140877.	2.5	7
263	Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. <i>AIDS Patient Care and STDs</i> , 2017, 31, 487-494.	2.5	7
264	Serious clinical events in HIV-positive persons with chronic kidney disease. <i>Aids</i> , 2019, 33, 2173-2188.	2.2	7
265	Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study. <i>Antibiotics</i> , 2021, 10, 1031.	3.7	7
266	JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3752.	2.4	7
267	Predictors of low ovarian reserve in cART-treated women living with HIV. <i>Medicine (United States)</i> , 2021, 100, e27157.	1.0	7
268	Early diagnosis of HIV infection in infants. <i>Aids</i> , 1989, 3, 391-396.	2.2	6
269	Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 171-174.	3.0	6
270	Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 1003-1007.	3.0	6

#	ARTICLE	IF	CITATIONS
271	Rhodococcus equi infection in a patient with spinocellular carcinoma of unknown origin. Journal of Medical Microbiology, 2008, 57, 1431-1433.	1.8	6
272	Exposure to Abacavir and Biomarkers of Cardiovascular Disease in HIV-1â€“Infected Patients on Suppressive Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, e98-e101.	2.1	6
273	Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort. Journal of the International AIDS Society, 2014, 17, 19653.	3.0	6
274	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. Journal of Antimicrobial Chemotherapy, 2014, 69, 3085-3094.	3.0	6
275	Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clinical Trials, 2018, 19, 52-60.	2.0	6
276	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. Journal of Infectious Diseases, 2021, 223, 632-637.	4.0	6
277	Invariant Natural Killer T (iNKT) Cells in HAART-Treated, HIV-Positive Patients with Bone and Cardiovascular Impairment. PLoS ONE, 2014, 9, e110287.	2.5	6
278	Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS ONE, 2018, 13, e0192627.	2.5	6
279	An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. New Microbiologica, 2015, 38, 443-90.	0.1	6
280	Women Facing HIV. Key Question on Women with HIV Infection: Italian Consensus Workshop. Infection, 2009, 37, 168-178.	4.7	5
281	Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. AIDS Research and Treatment, 2012, 2012, 1-7.	0.7	5
282	Durability of Lopinavir/ritonavir mono-therapy in individuals with viral load ≤50 copies/mL in the observational setting. Antiviral Therapy, 2013, 19, 319-324.	1.0	5
283	Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. Journal of the International AIDS Society, 2014, 17, 19825.	3.0	5
284	Highlights on HIV eradication in 2013. Aids, 2014, 28, 1-7.	2.2	5
285	T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside retrotranscriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study. Antiviral Therapy, 2015, 21, 133-142.	1.0	5
286	Illness Representations of HIV Positive Patients Are Associated with Virologic Success. Frontiers in Psychology, 2016, 7, 1991.	2.1	5
287	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. Journal of Antimicrobial Chemotherapy, 2017, 72, 2862-2868.	3.0	5
288	Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature. BMC Infectious Diseases, 2018, 18, 8.	2.9	5

#	ARTICLE	IF	CITATIONS
289	HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients. <i>PLoS ONE</i> , 2018, 13, e0190302.	2.5	5
290	Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings. <i>Aids</i> , 2019, 33, S271-S281.	2.2	5
291	Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. <i>Journal of the International AIDS Society</i> , 2021, 24, e25690.	3.0	5
292	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , 2016, 11, e0160761.	2.5	5
293	Three case reports of West Nile virus neuroinvasive disease: lessons from real-life clinical practice. <i>BMC Infectious Diseases</i> , 2021, 21, 1132.	2.9	5
294	Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2001, 6, 195-198.	1.0	5
295	Predictive role of the three-month CD4 cell count in the long-term clinical outcome of the first HAART regimen. <i>Biomedicine and Pharmacotherapy</i> , 2001, 55, 16-22.	5.6	4
296	Cerebrovascular disease in highly active antiretroviral therapy-treated individuals: Incidence and risk factors. <i>Journal of NeuroVirology</i> , 2005, 11, 34-37.	2.1	4
297	Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients. <i>Journal of Visualized Experiments</i> , 2011, , .	0.3	4
298	Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19806.	3.0	4
299	Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19769.	3.0	4
300	Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 258-267.	2.1	4
301	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 465-471.	2.1	4
302	Haemoptysis and fever in a young refugee from Somalia. <i>International Journal of Infectious Diseases</i> , 2018, 77, 57-60.	3.3	4
303	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. <i>BMC Public Health</i> , 2019, 19, 1291.	2.9	4
304	Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1857-1865.	2.9	4
305	Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen. <i>Antiviral Therapy</i> , 2019, 24, 321-331.	1.0	4
306	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , 2021, 35, 2025-2033.	2.2	4

#	ARTICLE	IF	CITATIONS
307	Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. <i>BMC Infectious Diseases</i> , 2021, 21, 557.	2.9	4
308	Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepalCONA Foundation Cohort Study. <i>Viruses</i> , 2021, 13, 1402.	3.3	4
309	Resilience, Psychological Well-Being and Daily Functioning Following Hospitalization for Respiratory Distress Due to SARS-CoV-2 Infection. <i>Healthcare (Switzerland)</i> , 2021, 9, 1161.	2.0	4
310	Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106406.	2.5	4
311	Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 132-137.	2.1	4
312	Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. <i>PLoS ONE</i> , 2017, 12, e0189045.	2.5	4
313	Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19. <i>Vaccines</i> , 2022, 10, 550.	4.4	4
314	HCV reinfection after HCV therapy among HIV/HCV coinfecting individuals in Europe. <i>HIV Medicine</i> , 2022, 23, 684-692.	2.2	4
315	Diagnosis of Virus-associated Opportunistic Diseases of the Central Nervous System in Patients with HIV Infection by Polymerase Chain Reaction on Cerebrospinal Fluid. <i>Annals of the New York Academy of Sciences</i> , 1994, 724, 170-172.	3.8	3
316	Vertebral fractures in AIDS patients within 6 months from highly active antiretroviral therapy initiation: two case reports. <i>Aids</i> , 2008, 22, 1094-1097.	2.2	3
317	The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro. <i>Journal of Global Antimicrobial Resistance</i> , 2016, 7, 1-7.	2.2	3
318	Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). <i>Journal of NeuroVirology</i> , 2018, 24, 679-694.	2.1	3
319	Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3391.	2.4	3
320	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac029.	0.9	3
321	Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment. <i>New Microbiologica</i> , 2018, 41, 112-117.	0.1	3
322	Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process. <i>HIV Medicine</i> , 2022, 23, 639-649.	2.2	3
323	Evaluation of the effect of protective genetic variants on cART success in HIV-1-infected patients. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2020, 34, 1553-1559.	0.7	3
324	Delayed-Type Hypersensitivity Skin Testing Can Predict CD4 Count Increase in HIV Patients With Poor Immunologic Response to HAART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 277-278.	2.1	2

#	ARTICLE	IF	CITATIONS
325	CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19509.	3.0	2
326	High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects. <i>Medicine (United States)</i> , 2016, 95, e4434.	1.0	2
327	Brief Report: Drop in CD4+ Counts Below 200 Cells/ μ L After Reaching (or Starting From) Values Higher than 350 Cells/ μ L in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 417-422.	2.1	2
328	Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 871-881.	2.9	2
329	Immune activation, inflammation and HIV DNA after 96-weeks of ATV/r monotherapy: a MODAt substudy. <i>Antiviral Therapy</i> , 2018, 23, 633-637.	1.0	2
330	Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients. <i>HIV Clinical Trials</i> , 2018, 19, 158-162.	2.0	2
331	Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study. <i>Clinical Drug Investigation</i> , 2019, 39, 1239-1249.	2.2	2
332	Chest pain and a left parasternal soft tissue swelling in an immunocompetent refugee with disseminated tuberculosis. <i>International Journal of Infectious Diseases</i> , 2020, 90, 116-118.	3.3	2
333	Impact of daily versus weekly service of infectious diseases consultation on hospital antimicrobial consumption: a retrospective study. <i>BMC Infectious Diseases</i> , 2020, 20, 812.	2.9	2
334	Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice. <i>Health Economics Review</i> , 2020, 10, 27.	2.0	2
335	Ability to Monitor National Responses to the HIV Epidemic "Beyond Viral Suppression" Findings From Six European Countries. <i>Frontiers in Public Health</i> , 2020, 8, 36.	2.7	2
336	Long-term positive effect of an educational antimicrobial stewardship program implemented in an Internal Medicine Department: a prospective analysis and a point prevalence survey on long-term effect. <i>Journal of Chemotherapy</i> , 2021, 33, 238-244.	1.5	2
337	HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa566.	0.9	2
338	Persistence of High Peripheral Activated CD8+ T-cells and Not a Low CD4:CD8 Ratio Predict cytologic HPV-Related Dysplasia in cART-Treated, HIV-Positive Subjects. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac046.	0.9	2
339	Prevalence of Chagas disease and strongyloidiasis among HIV-infected Latin American immigrants in Italy " The CHILI study. <i>Travel Medicine and Infectious Disease</i> , 2022, 48, 102324.	3.0	2
340	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. <i>HIV Medicine</i> , 2022, 23, 585-598.	2.2	2
341	HIV priorities by Italian AIDS advocacy groups: information on prevention (still) comes first. An on-line survey. <i>Epidemiologia E Prevenzione</i> , 2019, 43, 270-274.	1.1	2
342	Sudden Cardiac Death in a Young HIV-Positive Man on Effective Antiretroviral Therapy. <i>Current HIV Research</i> , 2008, 6, 560-562.	0.5	1

#	ARTICLE	IF	CITATIONS
343	Factors associated with HPV-DNA clearance in a cohort of HIV-positive patients: role of cART and gender. <i>Journal of the International AIDS Society</i> , 2014, 17, 19717.	3.0	1
344	Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression. <i>PLoS ONE</i> , 2019, 14, e0212075.	2.5	1
345	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≥ 50 copies/mL: does estimated glomerular filtration rate matter?. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106154.	2.5	1
346	Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepalCONA foundation cohorts. <i>Digestive and Liver Disease</i> , 2020, 52, 447-451.	0.9	1
347	Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss. <i>Scientific Reports</i> , 2021, 11, 9632.	3.3	1
348	SARS-CoV-2 and the nervous system: review on pathogenesis of nervous system SARS-CoV-2 damage. , 0, , .		1
349	Partnership of HIV-Infected Women and Health Status. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 39, 502-503.	2.1	0
350	Long-term probability of detecting drug-resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection. <i>Journal of the International AIDS Society</i> , 2010, 13, O4.	3.0	0
351	Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis. <i>BMC Health Services Research</i> , 2012, 12, 38.	2.2	0
352	Viro-immunological characterization of naïve patients with high cerebrospinal fluid (CSF) HIV RNA. <i>Journal of the International AIDS Society</i> , 2014, 17, 19710.	3.0	0
353	Reply to Manfredi. <i>Journal of Infectious Diseases</i> , 2015, 211, 1357-9.	4.0	0
354	A 20-year-old girl with an unusual febrile illness. <i>Internal and Emergency Medicine</i> , 2021, , 1.	2.0	0
355	Renal microsporidiosis due to <i>Encephalitozoon cuniculi</i> in an HIV/AIDS patient with persistent fever and kidney injury. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1439-1440.	6.0	0
356	A Quantitative Estimate of the Expected Shortening of the Median Isolation Period of Patients With COVID-19 After the Adoption of a Symptom-Based Strategy. <i>Frontiers in Public Health</i> , 2021, 9, 639347.	2.7	0
357	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. <i>PLoS ONE</i> , 2016, 11, e0156360.	2.5	0
358	Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 471.	2.4	0
359	Beyond Italian guidelines in the management of HIV-positive patient. <i>Infezioni in Medicina</i> , 2020, 28, 587-596.	1.1	0
360	<sc>HIV</sc>NAAT use for early detection of <sc>HIV</sc> infection among high-risk men who have sex with men in Italy. <i>HIV Medicine</i> , 2023, 24, 239-241.	2.2	0